Initial information for this Clinical Study case, AER number 1083565, was received on 29/Jun/2012 from a hysician 
and concerns a 63 Years old Male patient (patient number 411111) enrolled in Study 
No medicalhistory was reported. Concurrent conditions included HYPERTENSION and DYSLIPEMIA. 
Concomitant medications included OMEPRAZOLE, IBUPROFEN, CAPTOPRIL, DEXTROMETHORPHAN 
HYDROBROMIDE (ROMILAR), AMLODIPINE BESILATE (ASTUDAL), CALCIUM FOLINATE (FOLIDAN), 
NYSTATIN (MYCOSTATIN), THIETHYLPERAZINE MALEATE (TORECAN), ACECLOFENAC (AIRTAL). 
On 21/May/2012, the patient started therapy with intravenous BEVACIZUMAB vials at a dose of 7.5 mg/kg every 21 
day and PEMETREXED DISODIUM (dose, route, form and frequency:not reported). On 15/Jun/2012, the patient 
developed DIARRHEA grade 2 which led to hospitalisation. On 25/Jun/2012, he received fluid therapy (physiologic) 
1000 cc, fluid therapy (glucosaline) 1000 cc and his hemoglobin was 8.8 g/dI (normal values:14-18 g/dI). On 
26/Jun/2012, he was transfused 2 bags of red blood cells concentrated. It was also reported that, the patient 
presented tenesmus and remains hospitalised. 
The outcome of DIARRHEA grade 2 was not reported. Therapy with BEVACIZUMAB was ongoing and there was 
insufficient information regarding therapy with PEMETREXED DISODIUM. 
The investigator assessed the causal relationship DIARRHEA grade 2 as related to BEVACIZUMAB and 
PEMETREXED DISODIUM. 
No further information was provided. 
Additional information was received on 11/Jun/2012 
Patient's weight was updated. 
On 26/Jun/2012, the patient received enema and was treated with SODIUM CITRATE/SODIUM LAURYL 
SULFOACETATE (MICRALAX) 2 units daily. On 11111111111b the patient developed grade 2 ANEMIA with 
hemoglobin value of 7.9 g/dI (normal range: 14-18). On 29/Jun/2012, the fluid therapy with physiological serum and 
glucosaline serum, enema and treatment with SODIUM CITRATE/SODIUM LAURYL SULFOACETATE was 
00. 0. On the_ the event of DIARRHEA grade 2 was resolved and the patient was discharged. 
Print Time: 02-SEP-2014 01:09 PM If a field Is blank, there Is no data for that field Page 112  of 831 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information 
No further information was provided 
Additional information was received on 14/Aug/2012. 
On the patient went to emergency room due to Fever and chest pain his blood test and thorax x-ray 
s o TORY INFECTION which lead to hospitalisation. On the same day test for Antigenemia legionella 
and pneumococcal was performed. On the same day he was treated with LEVOFLOXACIN at a dose of 500mg, 
PARACETAMOL at a dose of 3g and CEFTRIAXONE SODIUM at a dose of 2g. 
The event of RESPIRATORY INFECTION was persisting. 
The Investigator assesed RESPIRATORY INFECTION as unrelated to BEVACIZUMAB and PEMETREXED 
DISODIUM but related to pre existing disease Lung cancer. 
No further information was provided. 
Additional information was received on 14/Aug/2012. 
It was reported that the patient has no previous history of diarrhea related such as bouts of acute diarrhea, mal-
absorption, immune-sppression, chronic gastrointestinal disorder or chronic antibiotic use. 
No further information was provided. 
Additional information was receive on 22/Aug/2012. 
On 11111111111 the event of RESPIRATORY INFECTION was resolved and the patient was discharged from the 
hospital. 
Additional information was received on 30/Aug/2012. 
On 21/May/2012, the patient started therapy with intravenous solution of BEVACIZUMAB 656.25 mg every three 
weeks (previously reported dosage form: vial) and intravenous solution of PEMETREXED 995 mg every three 
weeks. 
No further information was provided. 
print Time: 02-SEP-2014 01:09 PM If a field Is blank, there is no data for that field Page 113 of 831 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information 
Additional information was provided on 30/Aug/2012. 
On 16/Aug/2012, the patient received the last dose of PEMETREXED DISODIUM and on 17/Aug/202 the patient 
received the last dose BEVACIZUMAB prior to the event of DYSPNEA. On the patient experienced 
DYSPNEA. On the same day, the patient was hospitalized due to DYSPNEA. On Computerized 
Tomogram scan revealed progressive disease. On G111.1 the patient died due to progression of lung 
cancer. 
DYSPNEA was persisting and the therapy with BEVACIZUMAB, PEMETREXED DISODIUM was ongoing at the 
time of death. 
The Investigator assessed the event of DYSPNEA as unrelated to BEVACIZUMAB and PEMETREXED DISODIUM 
but related to pre-existing/underlying disease of lung cancer. 
No further information was provided. 
Additional information was received on 06 September 2012. 
On111.11111111111% the patient went to emergency room and was hospitalised due to dyspnea in the cardiology, 
pneu  0. y department and the final diagnosis was acute ischemia. On the same day, he was treated with 
tevoftoxacin r  e  g, salbutamol/salbutamol sulfate 800mcg and ipratropium bromide 160mcg. On 41111111111111111 
0 0 0 C culture was done (results not provided). On 20 August 2012, the therapy with levofloxacin and ceftriaxone 
was S 0 0 0  . On the same day, he was started on meropenem 3gm. On 20 August 2012, urine culture was done 
(mutts not provided). On 28 August 2012, the therapy with salbutamol/salbutamol sulfate, meropenem and 
ipratropium bromide was stopped. 
The physician assessed the fatal event of acute ischemia as unrelated to bevacizumab and pemetrexed disodium 
and related to pre-existing underlying disease of lung cancer. 
No further information was provided. 
Additional information was received on 26/Sep/2012. 
Concomitant medication included METHYLPREDNISOLONE and MORPHIC CLORURE. 
Event term ACUTE ISCHEMIA was amended to CARDIAC ISCHEMIA. 
Print Time: 02-SEP-2014 01:09 PM If a field is blank, there is no data for that field Page 114  of 831 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information 
On blood culture showed negative result. On MUM urine culture showed negative result. On 
, CT scan of chest showed, progression of disease. 
The physician assessed the fatal event of CARDIAC ISCHEMIA as unrelated to bevacizumab and pemetrexed 
disodium and related to pre-existing underlying disease of lung cancer. 
No further information was provided. 
Additional information was received on 06/Nov/2013. 
The physician assessed the fatal event of CARDIAC ISCHEM1A as related to bevacizumab (previously reported as 
unrelated to bevacizumab). 
No further information was provided. 
Additional information was received on 08/Nov/2013. 
Concomitant medications included cyanocobalamin/folic acid and cyanocobalamin 
No further information was provided.